A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly

Exclusion Criteria

• •For Roll-over Patients from NCT04076462:
• •Unresolved, drug-related serious adverse event (SAE) from the preceding trial
• •Patients with a clinically significant or unstable medical or surgical condition that may preclude safe and complete trial participation
• •For New Patients:
• •Have received medical treatment for acromegaly with pasireotide (within 6 months prior to screening), pegvisomant (within 3 months prior to screening), dopamine agonists (within 3 months prior to screening) or other investigational agents (within 30 days or 5 half-lives prior to screening \[whichever is longer\]
• •Patients who usually take octreotide LAR or lanreotide ATG less frequently than every 4 weeks (e.g. every 6 weeks or 8 weeks)
• •Patients with compression of the optic chiasm causing any visual field defect for whom surgical intervention is indicated
• •Patients who have undergone major surgery/surgical therapy for any cause within 1 month from screening
• •Patients who have undergone pituitary surgery within 6 months prior to screening
• •Patients who have received prior pituitary irradiation within 3 years prior to screening
• •Patients with poorly controlled diabetes mellitus (hemoglobin A1c \>8.0%)